NFKB1 and cancer: Therefore, disruption of NF‐κB not only synergizes with copper chelators to overcome drug resistance and cuproplasia, but also combines with copper ionophores to facilitate cuproptosis, providing a dual approach for combating chronic inflammation‐driven cancers.